Nipent pentostatin: Phase IV data

Results from an open-label, U.S. Phase IV study in 112 high-risk patients showed that reduced

Read the full 155 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE